文献速递糖尿病

恩格列净的有效性与安全性:EMPRISE 研究的最终结果

Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
PubMed 文献 · Diabetologia · 2024-03-21

EMPRISE 队列研究基于美国医疗保险与商业理赔数据库,纳入 2014 至 2019 年启动恩格列净或二肽基肽酶-4 抑制剂(DPP-4i)的 ≥18 岁 2 型糖尿病个体,经 1:1 倾向性评分匹配后得到 115,116 对。与 DPP-4i 相比,恩格列净与心肌梗死/卒中、心力衰竭住院、主要不良心血管事件及心血管死亡/心力衰竭住院风险降低相关,但糖尿病酮症酸中毒风险升高。

要点

  • 与 DPP-4i 相比,恩格列净与心肌梗死/卒中风险降低相关(HR 0.88,95%CI 0.81–0.96)。
  • 恩格列净与心力衰竭住院风险降低相关(HR 0.50,95%CI 0.44–0.56)。
  • 恩格列净与糖尿病酮症酸中毒风险升高相关(HR 1.78,95%CI 1.44–2.19)。

核心结论

  • 与 DPP-4i 相比,恩格列净与心肌梗死或卒中、心力衰竭住院、主要不良心血管事件及心血管死亡或心力衰竭住院复合终点的风险降低相关。
  • 与 DPP-4i 相比,恩格列净与糖尿病酮症酸中毒风险升高相关,与急性肾损伤、低血糖及视网膜病变进展风险降低相关,下肢截肢、非椎体骨折、肾脏和肾盂癌及膀胱癌的短期风险无差异。

研究设计与样本

  • EMPRISE 为队列研究,旨在通过电子医疗数据库定期监测恩格列净的安全性和有效性,为期 5 年。
  • 研究纳入 2014 至 2019 年美国医疗保险和商业理赔数据库中 ≥18 岁、启动恩格列净或 DPP-4i 的 2 型糖尿病个体。
  • 经 143 项基线特征 1:1 倾向性评分匹配后,共识别 115,116 对匹配个体。

主要发现

  • 与 DPP-4i 相比,恩格列净与心肌梗死/卒中风险降低相关(HR 0.88,95%CI 0.81–0.96;率差 -2.08,95%CI -3.26 至 -0.90)。
  • 与 DPP-4i 相比,恩格列净与心力衰竭住院风险降低相关(HR 0.50,95%CI 0.44–0.56;率差 -5.35,95%CI -6.22 至 -4.49)。
  • 与 DPP-4i 相比,恩格列净与主要不良心血管事件风险降低相关(HR 0.73,95%CI 0.62–0.86;率差 -6.37,95%CI -8.98 至 -3.77)。
  • 与 DPP-4i 相比,恩格列净与心血管死亡/心力衰竭住院复合终点风险降低相关(HR 0.57,95%CI 0.47–0.69;率差 -10.36,95%CI -12.63 至 -8.12)。
  • 与 DPP-4i 相比,恩格列净与糖尿病酮症酸中毒风险升高相关(HR 1.78,95%CI 1.44–2.19;率差 1.59,95%CI 1.08–2.09),与急性肾损伤(HR 0.62,95%CI 0.54–0.72)、低血糖(HR 0.75,95%CI 0.67–0.84)及视网膜病变进展(HR 0.78,95%CI 0.63–0.96;率差 -9.49,95%CI -16.97 至 -2.10)风险降低相关。

关键数值与推荐

  • 绝对获益在老年个体及有动脉粥样硬化性心血管疾病或心力衰竭病史者中更大。
  • 恩格列净与 DPP-4i 相比,下肢截肢、非椎体骨折、肾脏和肾盂癌及膀胱癌的短期风险无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Limited evidence exists on the comparative safety and effectiveness of empagliflozin against alternative glucose-lowering medications in individuals with type 2 diabetes with the broad spectrum of cardiovascular risk. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) cohort study was designed to monitor the safety and effectiveness of empagliflozin periodically for a period of 5 years with data collection from electronic healthcare databases. METHODS: We identified individuals ≥18 years old with type 2 diabetes who initiated empagliflozin or dipeptidyl peptidase-4 inhibitors (DPP-4i) from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we identified four a priori-defined effectiveness outcomes: (1) myocardial infarction (MI) or stroke; (2) hospitalisation for heart failure (HHF); (3) major adverse cardiovascular events (MACE); and (4) cardiovascular mortality or HHF. Safety outcomes included lower-limb amputations, non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), severe hypoglycaemia, retinopathy progression, and short-term kidney and bladder cancers. We estimated HRs and rate differences (RDs) per 1000 person-years, overall and stratified by age, sex, baseline atherosclerotic cardiovascular disease (ASCVD) and heart failure. RESULTS: We identified 115,116 matched pairs. Compared with DPP-4i, empagliflozin was associated with lower risks of MI/stroke (HR 0.88 [95% CI 0.81, 0.96]; RD -2.08 [95% CI (-3.26, -0.90]), HHF (HR 0.50 [0.44, 0.56]; RD -5.35 [-6.22, -4.49]), MACE (HR 0.73 [0.62, 0.86]; RD -6.37 [-8.98, -3.77]) and cardiovascular mortality/HHF (HR 0.57 [0.47, 0.69]; RD -10.36 [-12.63, -8.12]). Absolute benefits were larger in older individuals and in those with ASCVD/heart failure. Empagliflozin was associated with an increased risk of DKA (HR 1.78 [1.44, 2.19]; RD 1.59 [1.08, 2.09]); decreased risks of AKI (HR 0.62 [0.54, 0.72]; RD -2.39 [-3.08, -1.71]), hypoglycaemia (HR 0.75 [0.67, 0.84]; RD -2.46 [-3.32, -1.60]) and retinopathy progression (HR 0.78 [0.63, 0.96)]; RD -9.49 [-16.97, -2.10]); and similar risks of other safety events. CONCLUSIONS/INTERPRETATION: Empagliflozin relative to DPP-4i was associated with risk reductions of MI or stroke, HHF, MACE and the composite of cardiovascular mortality or HHF. Absolute risk reductions were larger in older individuals and in those who had history of ASCVD or heart failure. Regarding the safety outcomes, empagliflozin was associated with an increased risk of DKA and lower risks of AKI, hypoglycaemia and progression to proliferative retinopathy, with no difference in the short-term risks of lower-extremity amputation, non-vertebral fractures, kidney and renal pelvis cancer, and bladder cancer.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Htoo PT, Tesfaye H, Schneeweiss S, et al. Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia. 2024. PMID: 38509341. doi:10.1007/s00125-024-06126-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。